Drug name - Kynamro
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7015315 | KASTLE THERAPS LLC | Gapped oligonucleotides |
Mar, 2023
(5 months from now) | |
| US7101993 | KASTLE THERAPS LLC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(10 months from now) | |
| US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(4 years from now) | |
| IN201107578P4 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Nov, 2023
(1 year, 1 month from now) | |
| IN219847B | KASTLE THERAPS LLC | An Antisense Compound And A Composition Thereof |
Nov, 2023
(1 year, 1 month from now) | |
| IN200501218P4 | KASTLE THERAPS LLC | An Antisense Compound And A Composition Thereof |
Nov, 2023
(1 year, 1 month from now) | |
| IN299478B | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Nov, 2023
(1 year, 1 month from now) | |
| EP604409B1 | KASTLE THERAPS LLC | Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression |
Jan, 2011
(11 years ago) | |
| EP604409A4 | KASTLE THERAPS LLC | Compositions And Methods For Detecting And Modulating Rna Activity And Gene Expression. |
Jan, 2011
(11 years ago) | |
| EP604409A1 | KASTLE THERAPS LLC | Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression |
Jan, 2011
(11 years ago) | |
| EP517859A1 | KASTLE THERAPS LLC | Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses |
Feb, 2011
(11 years ago) | |
| EP517859A4 | KASTLE THERAPS LLC | Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses |
Feb, 2011
(11 years ago) | |
| EP517859B1 | KASTLE THERAPS LLC | Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses |
Feb, 2011
(11 years ago) | |
| EP529008A4 | KASTLE THERAPS LLC | Modulation Of Gene Expression Through Interference With Rna Secondary Structure |
Apr, 2011
(11 years ago) | |
| EP529008A1 | KASTLE THERAPS LLC | Modulation Of Gene Expression Through Interference With Rna Secondary Structure |
Apr, 2011
(11 years ago) | |
| EP529008B1 | KASTLE THERAPS LLC | Modulation Of Gene Expression Through Interference With Rna Secondary Structure |
Apr, 2011
(11 years ago) | |
| EP544757A4 | KASTLE THERAPS LLC | Novel Polyamine Conjugated Oligonucleotides |
Jun, 2011
(11 years ago) | |
| EP544757A1 | KASTLE THERAPS LLC | Novel Polyamine Conjugated Oligonucleotides |
Jun, 2011
(11 years ago) | |
| EP544757B1 | KASTLE THERAPS LLC | Novel Polyamine Conjugated Oligonucleotides |
Jun, 2011
(11 years ago) | |
| EP544716A4 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Cell Adhesion |
Jul, 2011
(11 years ago) | |
| EP544716A1 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Cell Adhesion |
Jul, 2011
(11 years ago) | |
| EP544716B1 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Cell Adhesion |
Jul, 2011
(11 years ago) | |
| EP544792A1 | KASTLE THERAPS LLC | Novel Nucleoside Analogs |
Aug, 2011
(11 years ago) | |
| EP544792B1 | KASTLE THERAPS LLC | Novel Nucleoside Analogs |
Aug, 2011
(11 years ago) | |
| EP549615B1 | KASTLE THERAPS LLC | Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression |
Aug, 2011
(11 years ago) | |
| EP549615A1 | KASTLE THERAPS LLC | Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression |
Aug, 2011
(11 years ago) | |
| EP544792A4 | KASTLE THERAPS LLC | Novel Nucleoside Analogs |
Aug, 2011
(11 years ago) | |
| EP549615A4 | KASTLE THERAPS LLC | Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression |
Aug, 2011
(11 years ago) | |
| EP544713A4 | KASTLE THERAPS LLC | Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections |
Aug, 2011
(11 years ago) | |
| EP544713A1 | KASTLE THERAPS LLC | Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections |
Aug, 2011
(11 years ago) | |
| EP544713B1 | KASTLE THERAPS LLC | Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections |
Aug, 2011
(11 years ago) | |
| EP586520A1 | KASTLE THERAPS LLC | Backbone Modified Oligonucleotide Analogs |
May, 2012
(10 years ago) | |
| EP586520A4 | KASTLE THERAPS LLC | Backbone Modified Oligonucleotide Analogs |
May, 2012
(10 years ago) | |
| EP586520B1 | KASTLE THERAPS LLC | Backbone Modified Oligonucleotide Analogs |
May, 2012
(10 years ago) | |
| EP586570B1 | KASTLE THERAPS LLC | Backbone Modified Oligonucleotide Analogues |
May, 2012
(10 years ago) | |
| EP586570A1 | KASTLE THERAPS LLC | Backbone Modified Oligonucleotide Analogues |
May, 2012
(10 years ago) | |
| EP586570A4 | KASTLE THERAPS LLC | Backbone Modified Oligonucleotide Analogues |
May, 2012
(10 years ago) | |
| EP590082A1 | KASTLE THERAPS LLC | Antisense Oligonucleotide Inhibition Of The Ras Gene |
Jun, 2012
(10 years ago) | |
| EP590082A4 | KASTLE THERAPS LLC | Antisense Oligonucleotide Inhibition Of The Ras Gene. |
Jun, 2012
(10 years ago) | |
| EP590082B1 | KASTLE THERAPS LLC | Antisense Oligonucleotide Inhibition Of The Ras Gene |
Jun, 2012
(10 years ago) | |
| EP655088A1 | KASTLE THERAPS LLC | Oligonucleotides Having Chiral Phosphorus Linkages |
Oct, 2012
(9 years ago) | |
| EP655088A4 | KASTLE THERAPS LLC | Oligonucleotides Having Chiral Phosphorus Linkages. |
Oct, 2012
(9 years ago) | |
| EP655088B1 | KASTLE THERAPS LLC | Oligonucleotides Having Chiral Phosphorus Linkages |
Oct, 2012
(9 years ago) | |
| EP724447A4 | KASTLE THERAPS LLC | Derivatized Oligonucleotides Having Improved Uptake And Other Properties |
Oct, 2012
(9 years ago) | |
| EP724447B1 | KASTLE THERAPS LLC | Derivatized Oligonucleotides Having Improved Uptake |
Oct, 2012
(9 years ago) | |
| EP724447A1 | KASTLE THERAPS LLC | Derivatized Oligonucleotides Having Improved Uptake |
Oct, 2012
(9 years ago) | |
| EP618925A1 | KASTLE THERAPS LLC | Antisense Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP1044987B1 | KASTLE THERAPS LLC | Gapped 2'-Modified Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP1044987A3 | KASTLE THERAPS LLC | Gapped 2'-Modified Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP1044987A2 | KASTLE THERAPS LLC | Gapped 2'-Modified Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP1695979A2 | KASTLE THERAPS LLC | Gapped Modified Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP1695979B1 | KASTLE THERAPS LLC | Gapped Modified Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP1695979A3 | KASTLE THERAPS LLC | Gapped 2' Modified Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP618925A4 | KASTLE THERAPS LLC | Gapped 2' Modified Oligonucleotides. |
Dec, 2012
(9 years ago) | |
| EP618925B2 | KASTLE THERAPS LLC | Antisense Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP618925B1 | KASTLE THERAPS LLC | Antisense Oligonucleotides |
Dec, 2012
(9 years ago) | |
| EP672180B1 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Protein Kinase C |
Feb, 2013
(9 years ago) | |
| EP672180A4 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Protein Kinase C. |
Feb, 2013
(9 years ago) | |
| EP672180A1 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Protein Kinase C |
Feb, 2013
(9 years ago) | |
| EP649429B1 | KASTLE THERAPS LLC | Heteroatomic Oligonucleoside Linkages |
May, 2013
(9 years ago) | |
| EP649429A1 | KASTLE THERAPS LLC | Heteroatomic Oligonucleoside Linkages |
May, 2013
(9 years ago) | |
| EP649429A4 | KASTLE THERAPS LLC | Heteroatomic Oligonucleoside Linkages. |
May, 2013
(9 years ago) | |
| EP651759B1 | KASTLE THERAPS LLC | Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof |
Jul, 2013
(9 years ago) | |
| EP1223173B1 | KASTLE THERAPS LLC | Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof |
Jul, 2013
(9 years ago) | |
| EP1223173A2 | KASTLE THERAPS LLC | Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof |
Jul, 2013
(9 years ago) | |
| EP1223173A3 | KASTLE THERAPS LLC | Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof |
Jul, 2013
(9 years ago) | |
| EP651759A1 | KASTLE THERAPS LLC | Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof |
Jul, 2013
(9 years ago) | |
| EP651759A4 | KASTLE THERAPS LLC | Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof. |
Jul, 2013
(9 years ago) | |
| EP662003A1 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Cell Adhesion |
Aug, 2013
(9 years ago) | |
| EP662003A4 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Cell Adhesion. |
Aug, 2013
(9 years ago) | |
| EP662003B1 | KASTLE THERAPS LLC | Oligonucleotide Modulation Of Cell Adhesion |
Aug, 2013
(9 years ago) | |
| EP672193B1 | KASTLE THERAPS LLC | Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament |
Sep, 2013
(9 years ago) | |
| EP672193A4 | KASTLE THERAPS LLC | Oligonucleotides Having A Conserved G 4? Core Sequence. |
Sep, 2013
(9 years ago) | |
| EP672193A1 | KASTLE THERAPS LLC | Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament |
Sep, 2013
(9 years ago) | |
| EP716604A4 | KASTLE THERAPS LLC | Thiol-Derivatized Nucleosides And Oligonucleosides |
Aug, 2014
(8 years ago) | |
| EP716604B1 | KASTLE THERAPS LLC | Thiol-Derivatized Nucleosides And Oligonucleosides |
Aug, 2014
(8 years ago) | |
| EP716604A1 | KASTLE THERAPS LLC | Thiol-Derivatized Nucleosides And Oligonucleosides |
Aug, 2014
(8 years ago) | |
| EP728139A4 | KASTLE THERAPS LLC | Gapped Oligonucleotides |
Sep, 2014
(8 years ago) | |
| EP728139A1 | KASTLE THERAPS LLC | Amine-Derivatized Nucleosides And Oligonucleosides |
Sep, 2014
(8 years ago) | |
| EP728139B1 | KASTLE THERAPS LLC | Amine-Derivatized Nucleosides And Oligonucleosides |
Sep, 2014
(8 years ago) | |
| EP734391A1 | KASTLE THERAPS LLC | Pna-Dna-Pna Chimeric Macromolecules |
Nov, 2014
(7 years ago) | |
| EP734391A4 | KASTLE THERAPS LLC | Pna-Dna-Pna Chimeric Macromolecules |
Nov, 2014
(7 years ago) | |
| EP734391B1 | KASTLE THERAPS LLC | Pna-Dna-Pna Chimeric Macromolecules |
Nov, 2014
(7 years ago) | |
| EP731807A1 | KASTLE THERAPS LLC | N-2 Substituted Purines |
Nov, 2014
(7 years ago) | |
| EP731807B1 | KASTLE THERAPS LLC | N-2 Substituted Purines |
Nov, 2014
(7 years ago) | |
| EP731807A4 | KASTLE THERAPS LLC | N-2 Substituted Purines |
Nov, 2014
(7 years ago) | |
| EP881914B1 | KASTLE THERAPS LLC | Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression |
Feb, 2017
(5 years ago) | |
| EP881914A1 | KASTLE THERAPS LLC | Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression |
Feb, 2017
(5 years ago) | |
| EP881914A4 | KASTLE THERAPS LLC | Gapped Oligonucleotides |
Feb, 2017
(5 years ago) | |
| EP1218395A4 | KASTLE THERAPS LLC | Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression |
Jan, 2020
(2 years ago) | |
| EP1218395A1 | KASTLE THERAPS LLC | Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression |
Jan, 2020
(2 years ago) | |
| EP1218395B1 | KASTLE THERAPS LLC | Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression |
Jan, 2020
(2 years ago) | |
| EP1325019A4 | KASTLE THERAPS LLC | Antisense Modulation Of Clusterin Expression |
Sep, 2021
(1 year, 25 days ago) | |
| EP1325019B1 | KASTLE THERAPS LLC | Antisense Modulation Of Clusterin Expression |
Sep, 2021
(1 year, 25 days ago) | |
| EP1325019A1 | KASTLE THERAPS LLC | Antisense Modulation Of Clusterin Expression |
Sep, 2021
(1 year, 25 days ago) | |
| EP2174945A1 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Jul, 2022
(2 months ago) | |
| EP2174945B1 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Jul, 2022
(2 months ago) | |
| EP2336318A1 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Nov, 2023
(1 year, 1 month from now) | |
| EP1569695A4 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Nov, 2023
(1 year, 1 month from now) | |
| EP1569695A2 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Nov, 2023
(1 year, 1 month from now) | |
| EP1569695B1 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Nov, 2023
(1 year, 1 month from now) | |
| EP2336318B1 | KASTLE THERAPS LLC | Antisense Modulation Of Apolipoprotein B Expression |
Nov, 2023
(1 year, 1 month from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 200MG/ML (200MG/ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.